Anti-CCL2 (Carlumab) -MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA

Anti-CCL2 (Carlumab) -MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab (HY-P99188) conjugated with the linker MC-Vc-PAB-DMEA-PEG2 and the DNA alkylator Duocarmycin SA (HY-12456) . Anti-CCL2 (Carlumab) -MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA can be used in cancer research[1][2].

Product Specifications

UNSPSC

12352203

Target

ADC Payload; Antibiotic; Antibody-Drug Conjugates (ADCs) ; Apoptosis; CCR; DNA Alkylator/Crosslinker

Related Pathways

Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage; GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Anti-CCL2(Carlumab)-MC-Vc-PAB-DMEA-PEG2-DuocarmycinSA]

References & Citations

[1]Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53 (10) :1020-7.|[2]Boyle KE, et al. Duocarmycin SA, a potent antitumor antibiotic, sensitizes glioblastoma cells to proton radiation. Bioorg Med Chem Lett. 2018 Sep 1;28 (16) :2688-2692.